drugset / Trial / NCT06908577

An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

NCT06908577

Phase 1 Completed 254 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.

Timeline

Start
2025-04-07
Primary completion
2025-11-25
Completion
2025-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Tozorakimab Monoclonal antibody Subcutaneous

Indications

No indication recorded.